Leggi questo articolo ad alta voce
Attiva il microfono e leggi con il tuo ritmo. Le parole si illuminano mentre procedi, e nulla ti ferma quando una viene pronunciata male.
Il tuo audio non arriva mai a MovaReader: a riconoscerlo è il tuo browser. Informativa sulla privacy
Accedi per conservare questa sessione nella cronologia delle letture.
Interpreting Amyloid and Tau Biomarkers in Preclinical Alzheimer's Disease
Advances in molecular neuroimaging have transformed how clinicians conceptualize neurodegenerative pathology, yet interpreting preclinical biomarkers requires exceptional epistemic caution. Positron emission tomography (PET) tracers such as Pittsburgh compound B and flortaucipir permit the in vivo detection of cortical amyloid-beta plaques and hyperphosphorylated tau neurofibrillary tangles years before clinical symptoms manifest. Under the National Institute on Aging and Alzheimer's Association research framework, positive biomarker status defines Alzheimer's disease biologically rather than syndromically. However, clinicians and researchers tend to emphasize that biological detection does not necessarily indicate immediate cognitive deterioration. Long-term prospective data suggest that a substantial proportion of amyloid-positive older adults may remain cognitively unimpaired throughout their natural lifespans.
The temporal relationship between protein aggregation and symptomatic onset remains arguably one of the most debated questions in modern neurology.